Neuphoria Therapeutics Inc.
NEUP
$4.66
-$0.01-0.21%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -127.10% | 118.82% | -11.51% | -178.88% | 679.54% |
| Total Depreciation and Amortization | -0.06% | 0.00% | 0.12% | 0.12% | -0.42% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 83.76% | -209.47% | 31.46% | 417.73% | 153.36% |
| Change in Net Operating Assets | 37.22% | -349.53% | -16.48% | 360.31% | -95.76% |
| Cash from Operations | 48.16% | -69.60% | -5.84% | -131.30% | 441.07% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -95.91% | 350.65% | 967.80% | -75.10% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | 754.66% | 45.05% |
| Cash from Financing | -100.00% | 350.65% | 361.70% | -39.38% | 1,141.67% |
| Foreign Exchange rate Adjustments | 78.44% | 1,614.87% | -139.31% | -41.65% | 130.72% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -132.97% | 1,620.41% | 80.20% | -122.29% | 439.03% |